News | March 24, 2009

Cianna Medical Granted Patents for SAVI Multi-Catheter Brachytherapy

March 24, 2009 - Cianna Medical said today that the U.S. Patent and Trademark Office issued two patents that are directly related to its SAVI multi-catheter brachytherapy device for the treatment of breast cancer.

The patents, Nos. 7,497,819 and 7,497,820 and titled “Expandable Brachytherapy Device,” represent the first patents issued for a family of applications focused in brachytherapy.

The SAVI multi-catheter open architecture design allows for the delivery of patient-specific radiation that minimizes the radiation dose to healthy tissue. Published reports and clinical experience show that most women who are excluded from balloon brachytherapy because of the location of the lesion or breast size can receive treatment with the SAVI delivery system.

Cianna received 510(k) clearance for SAVI from the U.S. Food and Drug Administration in August 2007 for use during brachytherapy procedures. For appropriate patients, SAVI is an advanced technology that may reduce treatment time to just five days, versus six to eight weeks for traditional radiation therapy.

For more information: www.CiannaMedical.com

Related Content

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Elekta, Esteya electronic brachytherapy system, Radiation Oncology Centres, first in Australia, skin cancer
News | Brachytherapy Systems | January 16, 2017
On Dec. 8, 2016, a female patient in her 60s became the first in the Australia/New Zealand region to receive electronic...
Overlay Init